Improving CAR T cell therapy for solid tumors
Tuning KITv CAR T cells for the solid tumor environment
['FUNDING_R01'] · SLOAN-KETTERING INST CAN RESEARCH · NIH-10943749
This study is testing a new type of CAR T cell therapy designed to help patients with malignant pleural mesothelioma by targeting a specific protein found in many tumors, with the hope of making the treatment more effective and safer for those who have already had other treatments.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SLOAN-KETTERING INST CAN RESEARCH (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10943749 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing CAR T cell therapy by developing a new type of CAR T cell that targets a specific cancer-associated antigen called mesothelin, which is found in many solid tumors. The approach involves administering these modified T cells directly into the pleural space of patients with malignant pleural mesothelioma, aiming to improve their ability to infiltrate tumors and resist suppression by the tumor environment. The study also explores the use of a novel receptor to enhance the effectiveness of the therapy while minimizing side effects. Patients who have previously received treatment will be monitored for safety and effectiveness, with the goal of improving survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with malignant pleural mesothelioma or other solid tumors that express mesothelin.
Not a fit: Patients with solid tumors that do not express mesothelin or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with solid tumors, potentially improving survival rates and reducing side effects.
How similar studies have performed: Previous studies have shown promising results with similar CAR T cell therapies targeting solid tumors, indicating potential for success in this novel approach.
Where this research is happening
NEW YORK, UNITED STATES
- SLOAN-KETTERING INST CAN RESEARCH — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ADUSUMILLI, PRASAD S. — SLOAN-KETTERING INST CAN RESEARCH
- Study coordinator: ADUSUMILLI, PRASAD S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.